Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by StockNews.com to “Buy”

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Friday.

Several other research analysts also recently weighed in on AUPH. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 3.3 %

Shares of Aurinia Pharmaceuticals stock opened at $9.37 on Friday. The company has a market capitalization of $1.34 billion, a P/E ratio of -62.46 and a beta of 1.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company has a fifty day moving average of $8.03 and a 200 day moving average of $6.75. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the transaction, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AUPH. Vanguard Group Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after acquiring an additional 21,119 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Aurinia Pharmaceuticals by 15.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 5,079 shares during the last quarter. Cetera Advisors LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 18.9% in the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 9,547 shares during the last quarter. Bank of New York Mellon Corp raised its position in Aurinia Pharmaceuticals by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock worth $2,791,000 after purchasing an additional 77,510 shares during the period. Finally, HighMark Wealth Management LLC raised its position in Aurinia Pharmaceuticals by 21.3% in the 2nd quarter. HighMark Wealth Management LLC now owns 91,196 shares of the biotechnology company’s stock worth $521,000 after purchasing an additional 16,000 shares during the period. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.